Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation

Tousif, S; Singh, AP; Umbarkar, P; Galindo, C; Wheeler, N; Cora, AT; Zhang, QK; Prabhu, SD; Lal, H

Lal, H (通讯作者)，UAB Univ Alabama Birmingham, Div Cardiovasc Dis, 1720 2nd Ave S, Birmingham, AL 35294 USA.

CIRCULATION RESEARCH, 2023; 132 (3): 267

Abstract

Background:The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic myelogenous leukemia patients with T315I (gatekeeper) muta......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索